Diabetes
Our history in diabetes
Novo Nordisk has been a world leader in diabetes care since 1923 and continues to pioneer the development of novel treatments for this serious condition.
We are constantly striving to improve the lives of people with diabetes by finding better methods of diabetes treatment and prevention.
Our partnering focus - compounds
Insulin and GLP-1 receptor peptide-agonists:
- Insulins and GLP-1s with novel therapeutic properties
- Optimized for oral delivery
- Modified duration of action
- Improved side-effect profile
Therapeutic proteins and peptides affecting:
- Glucose regulation
- Without inducing hypoglycaemia and/or
- Without inducing weight gain and/or
- With anti-obesity effects and/or
- With anti-hyperlipidaemia/anti-atherosclerosis effects
- Insulin secretion
- Insulin resistance
- Beta-cell mass
- Obesity
- Inflammation related to diabetes and obesity
- Prevention/progression of diabetes
Our partnering focus - technologies
Protein and peptide technologies:
- Expression
- Modification
- Production
Formulation and drug delivery technologies for proteins and peptides:
- Liquid
- Oral
- Sustained/triggered release
Diabetes Research Unit
For other enquiries
Contact
For further information please contact Diabetes Strategy & Sourcing
Download
Please download the Novo Nordisk:
Partnering folder
